Like the innate antibodies she studies, Nicole Baumgarth acts fast in the face of adversity. When she wasn't allowed to enroll in the African livestock program that she had her heart set on in college, Baumgarth switched to mice. When Reagan was elected, she opted for the post-doc in Australia. When a car hit her bicycle soon after moving to the US for a second post-doc, she didn't head home defeated. Alone in the hospital with a five-part fracture in her left leg, she had no one to call save one former lab mate. Although the injury has left her limping 11 years and two surgeries later, she hasn't missed a step. Baumgarth came to California by way of Germany, the UK, and Australia. It was in Brisbane that she first got her hands on influenza, a virus of which she admiringly says elicits a nearly perfect immune response. In 1996 she moved to Stanford to work with Leonore Herzenberg on B cell responses to influenza (1) . Now an associate professor at the University of California, Davis, Baumgarth finds herself back in a veterinary school environment. There, she takes a nontraditional approach to looking at how the body protects itself from various pathogens that plague society today. Besides influenza, that list includes Lyme disease, malaria, HPV, and HIV (2). She puts B cells above all else academic, focusing on the innate regulation of antibody production in response to infection (3) (4) (5) (6) . 
So you think fl u vaccines work?
When the vaccine works, it works great. Last year, though, it didn't work because it wasn't perfectly matched [to the prevalent virus strain].
How might your research on infl uenza help create a better fl u vaccine?
One focus of my lab is to look at the cells that make broadly reactive antibodies to all sorts of diff erent pathogens in a nonspecifi c way. We want to see if we can use the properties of these antibodies in a vaccine approach to either increase their numbers or to make them go to the site where they're needed for protection.
Taking advantage of a nonspecifi c, innate response sounds quite diff erent from most of today's vaccines. What makes these natural antibodies so attractive? At Stanford we found that you need the natural antibodies to be protected from flu. If you don't have them, the virus will replicate faster; it's one of the things that can keep the initial infection in check. When we first looked at natural antibodies in the serum, nothing happened-the serum antibody levels stayed the same before and after the infection. Then when I started my own lab, I thought maybe it was because we had looked in the blood. The [influenza] infection actually occurs in the respiratory tract, not in the blood. So we looked in the respiratory tract, and we saw that the B1 cells accumulate there after infection. The interesting thing is that these cells are no more or less antigen specific than they were before infection… there is no expansion of a specific response, none of the things you associate with an adaptive immune response. We think an innate signal is driving these cells to the site of infection. We are now trying to find out the identity of the innate signal.
How might natural antibodies be used to fi ght the fl u?
Nobody has a problem with CD4, CD8, Th17, or Th2, but when people think of the B cell response they think, "Oh, they are just antibodies. 
What has to happen before the development of a nonspecifi c fl u vaccine can begin?
The big challenge is to fi nd ways to track them [B1 cells], because if you want to make a vaccine that stimulates these cells you need to be able to monitor them. Once we can do that we can ask questions like: Are people less protected from mutated viruses because they don't have enough of the natural antibody? That's so crucial. I wish more people would think about the immune system as a whole system. There is an emphasis on mechanisms and molecular analyses, but at the end of the day all the mechanisms work together. I get frustrated when I hear people saying that one arm of the immune system isn't important in this disease and another arm isn't important in that disease; they're all important. They all act together. In a given disease process one might be stronger, but at the end of the day they act together and that [complexity] When I learned about antibody production…there was just something about it, I just loved it. I had to work on T cells for four years, but the moment I could, I switched back to B cells. I don't know why. Bizarre.
